Anna V. Tinker

Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor α Testing in Ovarian Cancer.

Journal: Current oncology (Toronto, Ont.)

Published: April 04, 2026

Differences in first-line chemosensitivity assessed by ELIMination rate constant K in advanced serous ovarian cancer: evidence from Western and Japanese Trials in a Gynecologic Cancer InterGroup meta-analysis.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: March 13, 2026

Lymph node involvement, surgery and adjuvant treatment in primary Endometrioid Ovarian carcinoma PAtients with eaRly-stage Disease (LEOPARD) - a multinational team initiative.

Journal: Gynecologic oncology

Published: February 01, 2026

CRI-CCTG-0003/IND.240 an immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC): Sub-studies A and B: Durvalumab (D) + mecbotamab vedotin (BA3011) or ozuriftamab vedotin (BA3021).

Journal: Cancer treatment and research communications

Published: September 30, 2025

Bridging historical evidence and contemporary strategies in the adjuvant treatment of early-stage epithelial ovarian cancer.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: August 08, 2025

Identifying high-risk relapse in early-stage I to II ovarian cancer using the CA125 ELIMination rate constant K (KELIM) score: a Gynecologic Cancer InterGroup individual patient-data meta-analysis.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: July 25, 2025

Collaborative team-based care implementation in ambulatory gynecological and lung cancer clinics.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: June 24, 2025

Long-Term Toxicities of Adolescent and Young Adults Who Underwent Radiation Therapy for Cervix Cancer: A Cross-Sectional Analysis.

Journal: Journal of adolescent and young adult oncology

Published: February 21, 2025

How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: October 22, 2024

Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor α Testing in Ovarian Cancer.

Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor α Testing in Ovarian Cancer.

Differences in first-line chemosensitivity assessed by ELIMination rate constant K in advanced serous ovarian cancer: evidence from Western and Japanese Trials in a Gynecologic Cancer InterGroup meta-analysis.

Differences in first-line chemosensitivity assessed by ELIMination rate constant K in advanced serous ovarian cancer: evidence from Western and Japanese Trials in a Gynecologic Cancer InterGroup meta-analysis.

Lymph node involvement, surgery and adjuvant treatment in primary Endometrioid Ovarian carcinoma PAtients with eaRly-stage Disease (LEOPARD) - a multinational team initiative.

Lymph node involvement, surgery and adjuvant treatment in primary Endometrioid Ovarian carcinoma PAtients with eaRly-stage Disease (LEOPARD) - a multinational team initiative.

CRI-CCTG-0003/IND.240 an immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC): Sub-studies A and B: Durvalumab (D) + mecbotamab vedotin (BA3011) or ozuriftamab vedotin (BA3021).

CRI-CCTG-0003/IND.240 an immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC): Sub-studies A and B: Durvalumab (D) + mecbotamab vedotin (BA3011) or ozuriftamab vedotin (BA3021).

Bridging historical evidence and contemporary strategies in the adjuvant treatment of early-stage epithelial ovarian cancer.

Bridging historical evidence and contemporary strategies in the adjuvant treatment of early-stage epithelial ovarian cancer.

Identifying high-risk relapse in early-stage I to II ovarian cancer using the CA125 ELIMination rate constant K (KELIM) score: a Gynecologic Cancer InterGroup individual patient-data meta-analysis.

Identifying high-risk relapse in early-stage I to II ovarian cancer using the CA125 ELIMination rate constant K (KELIM) score: a Gynecologic Cancer InterGroup individual patient-data meta-analysis.

Collaborative team-based care implementation in ambulatory gynecological and lung cancer clinics.

Collaborative team-based care implementation in ambulatory gynecological and lung cancer clinics.

Long-Term Toxicities of Adolescent and Young Adults Who Underwent Radiation Therapy for Cervix Cancer: A Cross-Sectional Analysis.

Long-Term Toxicities of Adolescent and Young Adults Who Underwent Radiation Therapy for Cervix Cancer: A Cross-Sectional Analysis.

ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety.

ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety.

Changes in female cancer diagnostic billing rates over the COVID-19 period in the Ontario Health Insurance Plan.

Changes in female cancer diagnostic billing rates over the COVID-19 period in the Ontario Health Insurance Plan.

Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer.

Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer.

How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes.

How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes.